Current media reports are warning of increased resitance to anti-biotics. One of the issues highlighted was a resistance (geddit!!??) by pharmaceutical giants to invest in drugs with a short product life (due to resitiance forming) and short prescription period (ie you're not on them for life). That got me thinking, why does UK plc not have a pharmaceutical wing? Surely that would; allow research proirities to be based on patient demand - not market demand, reduce NHS drug bills and give you a bargaining chip with the private sector for licence sharing? Any ideas?